ESMO 2025 | Soluble MAdCAM-1 as a prognostic biomarker in metastatic RCC
Marc Machaalani, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from three clinical trials, JAVELIN Renal 101 (NCT02684006), SURF (NCT02689167), and NIVOREN (NCT03013335), evaluating soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma (RCC). Elevated baseline levels and early increases in soluble MAdCAM-1 were linked to better progression-free and overall survival. The results highlight a potential role for microbiota-related biomarkers in guiding therapy and optimizing immunotherapy outcomes in RCC. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
